Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy. Issue 9 (28th May 2020)

• Record Type: Journal Article
• Authors: Tambaro, Francesco Paolo; Khazal, Sajad; Nunez, Cesar; Ragoonanan, Dristhi; Tewari, Priti; Petropoulos, Demetrios; Kebriaei, Partow; Wierda, William George; Mahadeo, Kris Michael
• Is Part Of: Clinical case reports. Volume 8:Issue 9(2020)
• Page Start: 1678
• Page End: 1681
• Publication Date: 2020-05-28
• Subjects: acute lymphoblastic leukemia -- blinatumomab -- chimeric antigen receptor; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.2918
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy. Abstract : The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.